BEG-I Nasal Spray
Bactroban (Mupirocin) 0.2%, Edetate Disodium (EDTA) 1%, Gentamicin 0.5%, and Itraconazole 1%.
BEG-I is a compounded medication recommended by leading infectious disease experts for the treatment of biotoxin illnesses. BEG-I has been found to be particularly important in the treatment process for MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staph), a staph infection that settles deep in the nasal cavity.  The highly resistant pathogens of MARCoNS shelter themselves in a protective biofilm that is impenetrable with antibiotics alone. Laboratory studies have shown topical antibiofilm treatment to be an effective option to combat antibiotic-resistant bacterial colonies.  This is a key step aiding in the recovery and healing process.
What’s in BEG-I Nasal Spray?
The active ingredients of BEG-I include two antibiotics- Bactroban (mupirocin) and Gentamicin, calcium chelator agent EDTA, and the antifungal agent Itraconazole. Topical antibiotics like Mupirocin have been widely used in the treatment of biofilm.  In a clinical trial on the efficacy of topical Bactroban (mupirocin) treatment in the sinuses of chronic sinusitis (CRS) patients, it was concluded that mupirocin could be useful in eliminating Staphylococcus aureus (S. aureus) biofilms present on the sinus mucosa of CRS patients and offer an additional treatment method for patients with recurring sinusitis.  EDTA works by breaking down the protective biofilm, allowing the antibiotics and antifungal to target the infected sinus cavity.  The I in BEG-I stands for Itraconazole, a powerful triazole antifungal agent often affiliated with the treatment of a range of fungal infections including chronic inflammatory response syndrome (CIRS).  Itraconazole works by hindering the formation of the fungal cell membrane. 
Forte Rx Compounding Pharmacy is the leading compounding pharmacy for mold and biotoxin illnesses. We offer BEG-I nasal spray along with a wide range of compounded medications for the treatment of infections and chronic illnesses related to mold exposure.
Please contact our clinical department today at (805) 427-9053 and ask to speak with one of our expert CIRS, mold/biotoxin illness, MCAS, sinus, and Lyme Disease clinical pharmacists about BEG-I Nasal Spray.
 Shoemaker’s Protocol for MARCoNS https://www.wondermakers.com/Portals/0/11-Step%20Treatment%20for%20Biotoxin%20Illness.pdf
 Sharma, D., Misba, L. & Khan, A.U. Antibiotics versus biofilm: an emerging battleground in microbial communities. Antimicrob Resist Infect Control 8, 76 (2019). https://doi.org/10.1186/s13756-019-0533-3
 Le, T., Psaltis, A., Tan, L. W., & Wormald, P.-J. (2008). The Efficacy of Topical Antibiofilm Agents in a Sheep Model of Rhinosinusitis. American Journal of Rhinology, 22(6), 560–567. https://doi.org/10.2500/ajr.2008.22.3232
 Goh, Y. H., & Goode, R. L. (2000). State of the Art Review: Current Status of topical nasal antimicrobial agents. The Laryngoscope, 110(6), 875–880. https://doi.org/10.1097/00005537-200006000-00001
 Ha KR, Psaltis AJ, Butcher AR, Wormald PJ, Tan LW. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope. 2008 Mar;118(3):535-40. doi: 10.1097/MLG.0b013e31815bf2e3. PMID: 18090864.
 Dr. Shoemaker’s 11-Step Treatment for Biotoxin Illness https://www.wondermakers.com/Portals/0/11-Step%20Treatment%20for%20Biotoxin%20Illness.pdf
 Kite, P., Eastwood, K., Sugden, S., & Percival, S. L. (2004). Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. Journal of clinical microbiology, 42(7), 3073–3076. https://doi.org/10.1128/JCM.42.7.3073-3076.2004
 Dixon DM, Walsh TJ. Antifungal Agents. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 76. Available from: https://www.ncbi.nlm.nih.gov/books/NBK8263/